Get your Emails warmed up and ready to send

Build sender reputation and reach more inboxes with automated email warmup.

Warm up your emails

Starting at $49/month

Start Warming Up

Chris Jaeggi

Chairman of the Board of Directors @Muvon Therapeutics Ag

Zug, CH
MOBILE NUMBERS
+91 *********19

Signup · Get unlimited contacts

WORK HISTORY

Oct 2020 — Present

Chairman of the Board of Directors @Muvon Therapeutics Ag

Zurich, CH

MUVON Therapeutics is a Biotech Spin-off from the University of Zurich with the goal of developing and commercializing an autologous cell therapy platform for the regeneration of skeletal muscle tissue. Our initial focus is developing a safe and effective treatment for stress urinary incontinences (SUI) in women, supporting them respectfully through their journey to a healthy life.

EDUCATION

1986 — 1991

University of Basel

MBA/ MEconomics, Marketing, Team work, Leadership

2005 — 2005

London Business School

Insights for Pharma

1982 — 1986

Fairleigh Dickinson University

Bachelor of Science (BSc), Chemistry

2011 — 2011

Harvard University

Organizational Leadership

ABOUT CHRIS JAEGGI

Seasoned commercial leader in a variety of strategic and operative roles, including in marketing, sales, commercial excellence, market analytics, business development, regional management, partnership and alliance management in top pharma and agile biotech companies. Outstanding track record of defining successful business strategies, rolling out and executing patient-centric global and regional brand launches, and reviving and accelerating growth of specialty care and orphan brands including in oncology, hematology, stem cell and organ transplantation, neurology, and psychiatry to personalize healthcare. I lead by example, I am able to build and maintain meaningful partnerships and implement purposeful operational plans with motivated teams.

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.